Effect of CYP2C19 Genotype on Inhibition of Platelet Aggregation in Hemodialysis Patients With Coronary Artery Disease

被引：0
|
作者：
Waseda, Katsuhisa
Saka, Yuki
Takashima, Hiroaki
Kurita, Akiyoshi
Ando, Hirohiko
Sakurai, Shinichiro
Suzuki, Akihiro
Sawada, Hiroaki
Sato, Shigeko
Nishikawa, Yoshinori
Amano, Tetsuya
机构：
来源：
CIRCULATION | 2016年 / 134卷
关键词：
Antiplatelet drugs; Prasugrel; Clopidogrel; Renal function; Genetics;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
14237
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Influence of CYP2C19 genotype on antiplatelet treatment outcomes after percutaneous coronary intervention in patients with coronary heart disease
    Yu, Dongbiao
    Ma, Likun
    Zhou, Junling
    Li, Longwei
    Yan, Wu
    Yu, Xiaofan
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 19 (05) : 3411 - 3418
  • [32] Gender Differences in Impact of CYP2C19 Polymorphism on Risk of Coronary Artery Disease
    Hokimoto, Seiji
    Akasaka, Tomonori
    Nakagawa, Kazuko
    Ogawa, Hisao
    CIRCULATION, 2014, 130
  • [33] Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients
    Lee, John Andrew
    Lee, Craig R.
    Reed, Brent N.
    Plitt, David C.
    Polasek, Melissa J.
    Howell, Lucius A.
    Cicci, Jonathan D.
    Tasca, Kristen E.
    Weck, Karen E.
    Rossi, Joseph S.
    Stouffer, George A.
    PHARMACOGENOMICS, 2015, 16 (04) : 303 - 313
  • [34] The effect of the CYP2C19*2 allele on cardiovascular outcomes in patients with coronary artery stenting: a prospective study
    Yang, Dahao
    Peng, Changnong
    Liao, Zhiyong
    Wang, Xiaoqing
    Guo, Wenyu
    Li, Jun
    ARCHIVES OF MEDICAL SCIENCE, 2019, 15 (04) : 837 - 844
  • [35] Effect of CYP2C19 and CYP2C9 Genotype on Concentration Prediction of Valproate in Epileptic Patients
    Jiang De-Chun
    Bai Xiangrong
    Zhang QingXia
    Lu Wei
    Wang YuQin
    Li Lin
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 : 179P - 179P
  • [36] The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir
    Burger, David M.
    Schwietert, H. Reinier
    Colbers, E. P. H. Angela
    Becker, Mark
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (02) : 250 - 252
  • [37] THE IMPACT OF CYP2C19 POLYMORPHISM ON CORONARY ARTERY SPASM IN PATIENTS WITH VASOSPASTIC ANGINA
    Mizobe, Michio
    Hokimoto, Seiji
    Chitose, Tadasuke
    Takaoka, Naoko
    Tsujita, Kenichi
    Kaikita, Koichi
    Kazuko, Nakagawa
    Ogawa, Hisao
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E440 - E440
  • [38] The effect of famotidine on the acid inhibition by lansoprazole in relation to CYP2C19 genotype status.
    Furuta, T
    Shirai, N
    Sugimoto, M
    Nakamura, A
    Okudaira, K
    Kajimura, M
    Hishida, A
    GASTROENTEROLOGY, 2005, 128 (04) : A426 - A426
  • [39] CYP2C19 Genotype and Cardiovascular Events
    Siasos, Gerasimos
    Tousoulis, Dimitris
    Stefanadis, Christodoulos
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (14): : 1483 - 1484
  • [40] CYP2C19 genotype: a moving target?
    Zembles, Tracy N.
    Marcuccilli, Charles J.
    Sander, Tara L.
    Simpson, Pippa
    PHARMACOTHERAPY, 2012, 32 (10): : E236 - E236
12345